NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"), of the important September...
Related Questions
Could the lawsuit trigger any regulatory scrutiny or additional investigations that might impact operations?
How likely is a settlement versus a court ruling, and what timeline could affect the stock price?
What is the estimated financial exposure (potential damages or penalties) for CAPR from this securities fraud lawsuit?
Is there a risk of forced delisting or suspension from NASDAQ due to the allegations?
How might this litigation affect CAPR's ability to raise capital or secure financing in the near term?
Will the lawsuit lead to any dilution of existing shareholders through settlement payments or issuance of new shares?
What precedent exists for similar biotech securities fraud cases, and how did those outcomes influence stock performance?
How is the market currently pricing in litigation risk for CAPR, and does the current stock price reflect an over‑ or underestimation of that risk?
What impact could a negative outcome have on CAPR's pipeline projects, partnerships, or collaborations?
Are there any insider trading restrictions or lock‑up periods being imposed on executives or major shareholders as a result of the case?